Early anatomical outcomes of faricimab vs aflibercept 2 mg in treatment-naïve neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: A head-to-head comparative study in Taiwan
Faricimab and aflibercept demonstrated comparable effects on BCVA, CMT, and SFCT. However, faricimab was associated with better early control of PED, SHRM, and HRF. Further prospective trials are needed to validate our findings.
Authors
- Chang-Chi Weng (ORCID: https://orcid.org/0000-0003-2178-5612)
- Shih‐Jen Chen (ORCID: https://orcid.org/0000-0001-9798-1578)
- De‐Kuang Hwang (ORCID: https://orcid.org/0000-0001-6346-8485)
- Yu-Bai Chou
- Tai‐Chi Lin (ORCID: https://orcid.org/0000-0003-1163-0457)
- Yi-Ming Huang (ORCID: https://orcid.org/0000-0003-0171-9255)
- Chieh-Han Yang (ORCID: https://orcid.org/0000-0002-6676-1440)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Journal of the Chinese Medical Association
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1097/jcma.0000000000001320
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71